Kairos Pharma (NYSEAMERICAN:KAPA) Coverage Initiated at Maxim Group

Equities research analysts at Maxim Group assumed coverage on shares of Kairos Pharma (NYSEAMERICAN:KAPA) in a research note issued on Thursday,Benzinga reports. The brokerage set a “buy” rating and a $4.00 price target on the stock. Maxim Group’s price target points to a potential upside of 330.11% from the stock’s current price.

Separately, D. Boral Capital restated a “buy” rating and set a $9.00 target price on shares of Kairos Pharma in a research note on Thursday, March 20th.

Kairos Pharma Trading Down 3.1 %

Shares of KAPA stock traded down $0.03 on Thursday, hitting $0.93. The stock had a trading volume of 9,385 shares, compared to its average volume of 2,468,510. The business has a 50 day simple moving average of $1.30. Kairos Pharma has a 52-week low of $0.85 and a 52-week high of $4.00.

Kairos Pharma Company Profile

We are a clinical-stage biopharmaceutical company advancing therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer and glioblastoma.